Keywords: Novartis, Synthetic Genomics, Cepheid, flu vaccines, Monitoring test

Novartis in deal with SVGI to develop influenza vaccines using revolutionary "synthetic genomics" technology and with Cepheid for monitoring test

Article | 08 October 2010

Print This

Swiss drug major Novartis (NOVN.VX) has entered an agreement with Synthetic Genomics Vaccines Inc (SGVI) to apply "synthetic genomics" ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in